期刊
ACS MEDICINAL CHEMISTRY LETTERS
卷 12, 期 2, 页码 267-274出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.0c00647
关键词
Farnesoid X receptor; NR1H4; bile acid receptor; nonalcoholic steatohepatitis; NASH
资金
- Aventis Foundation
A new FXR modulator chemotype has been discovered with tunable activity between agonism and antagonism through minor structural modifications, showing high selectivity and binding affinities. This new FXR ligand compound demonstrates good metabolic stability in cells and can serve as a novel scaffold for FXR-targeted drug discovery.
Therapeutic modulation of the bile acid-sensing transcription factor farnesoid X receptor (FXR) is an appealing strategy to counteract hepatic and metabolic diseases. Despite the availability of several highly potent FXR agonists structural diversity of FXR modulators is limited, and new ligand scaffolds are needed. Here we report structure-activity relationship elucidation of a new FXR modulator chemotype whose activity can be tuned between agonism and antagonism by two minor structural modifications. Starting from a weak FXR/PPAR agonist, we have developed selective FXR activators and antagonists with nanomolar to low-micromolar potencies and binding affinities. The new FXR ligand chemotype modulates the FXR activity in the native cellular setting, is endowed with favorable metabolic stability, and lacks cytotoxicity. It valuably expands the collection of FXR modulators as a new scaffold for FXR-targeted drug discovery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据